NZ573348A - p38 MAP KINASE INHIBITORS - Google Patents

p38 MAP KINASE INHIBITORS

Info

Publication number
NZ573348A
NZ573348A NZ573348A NZ57334807A NZ573348A NZ 573348 A NZ573348 A NZ 573348A NZ 573348 A NZ573348 A NZ 573348A NZ 57334807 A NZ57334807 A NZ 57334807A NZ 573348 A NZ573348 A NZ 573348A
Authority
NZ
New Zealand
Prior art keywords
amino
cyclopentyl
phenyl
alkyl
oxopyridin
Prior art date
Application number
NZ573348A
Other languages
English (en)
Inventor
David Charles Festus Moffatt
Stephane Pintat
Stephen Davies
Original Assignee
Chroma Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0608855A external-priority patent/GB0608855D0/en
Priority claimed from GB0613914A external-priority patent/GB0613914D0/en
Application filed by Chroma Therapeutics Ltd filed Critical Chroma Therapeutics Ltd
Publication of NZ573348A publication Critical patent/NZ573348A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ573348A 2006-05-04 2007-05-01 p38 MAP KINASE INHIBITORS NZ573348A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0608855A GB0608855D0 (en) 2006-05-04 2006-05-04 Inhibitors of MAP kinase enzymes
GB0613914A GB0613914D0 (en) 2006-07-13 2006-07-13 Inhibitors of p38 map kinase
PCT/GB2007/001596 WO2007129040A1 (en) 2006-05-04 2007-05-01 p38 MAP KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
NZ573348A true NZ573348A (en) 2012-01-12

Family

ID=38268953

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ573348A NZ573348A (en) 2006-05-04 2007-05-01 p38 MAP KINASE INHIBITORS

Country Status (15)

Country Link
US (1) US8044211B2 (enExample)
EP (1) EP2013175B9 (enExample)
JP (1) JP5340918B2 (enExample)
KR (1) KR101429780B1 (enExample)
CN (1) CN102942520B (enExample)
AU (1) AU2007246869B2 (enExample)
BR (1) BRPI0711310B8 (enExample)
CA (1) CA2650970C (enExample)
CY (1) CY1118518T1 (enExample)
DK (1) DK2013175T5 (enExample)
ES (1) ES2605727T3 (enExample)
HU (1) HUE033281T2 (enExample)
NZ (1) NZ573348A (enExample)
PT (1) PT2013175T (enExample)
WO (1) WO2007129040A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0619753D0 (en) * 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
CA2668070A1 (en) * 2006-10-30 2008-05-08 Chroma Therapeutics Ltd. Hydroxamates as inhibitors of histone deacetylase
UA98961C2 (uk) 2007-06-27 2012-07-10 Астразенека Аб Похідні піразинону та їх застосування у лікуванні легеневих захворювань
WO2009060160A1 (en) * 2007-11-07 2009-05-14 Chroma Therapeutics Ltd. P38 map kinase inhibitors
GB0803747D0 (en) 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
ES2427892T3 (es) * 2008-02-29 2013-11-04 Chroma Therapeutics Limited Inhibidores de MAP quinasa p38
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
AR073711A1 (es) 2008-10-01 2010-11-24 Astrazeneca Ab Derivados de isoquinolina
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
SI3222616T1 (sl) 2012-10-17 2019-10-30 Macrophage Pharma Ltd N-(2-(4-(6-amino-5-(2,4-difluorobenzoil)-2-oksopiridin-1(2H)-IL)-3,5- difluorofenil)etil)-L-alanin in njegov terbutil ester
GB201306901D0 (en) * 2013-04-16 2013-05-29 Chroma Therapeutics Ltd Combination
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL163957A0 (en) * 2002-03-14 2005-12-18 Bayer Healthcare Ag Monocyclic aroylpyridinones as antiinflammatory agents
MX2007013257A (es) * 2005-05-05 2008-01-21 Chroma Therapeutics Ltd Conjugados de ester de alfa-aminoacido-farmaco hidrolizables por carboxilesterasa.
ES2427892T3 (es) * 2008-02-29 2013-11-04 Chroma Therapeutics Limited Inhibidores de MAP quinasa p38

Also Published As

Publication number Publication date
CA2650970A1 (en) 2007-11-15
BRPI0711310B8 (pt) 2021-05-25
WO2007129040A1 (en) 2007-11-15
BRPI0711310A2 (pt) 2011-12-06
EP2013175B9 (en) 2020-11-11
CY1118518T1 (el) 2017-07-12
ES2605727T9 (es) 2020-12-11
DK2013175T5 (da) 2020-12-21
AU2007246869A1 (en) 2007-11-15
HUE033281T2 (en) 2017-11-28
US8044211B2 (en) 2011-10-25
AU2007246869B2 (en) 2012-10-18
EP2013175B1 (en) 2016-11-09
PT2013175T (pt) 2017-02-14
CA2650970C (en) 2014-09-16
KR101429780B1 (ko) 2014-08-18
KR20090014187A (ko) 2009-02-06
US20090099185A1 (en) 2009-04-16
ES2605727T3 (es) 2017-03-16
CN102942520A (zh) 2013-02-27
EP2013175A1 (en) 2009-01-14
JP5340918B2 (ja) 2013-11-13
DK2013175T3 (en) 2017-02-20
JP2009535385A (ja) 2009-10-01
CN102942520B (zh) 2015-03-04
BRPI0711310B1 (pt) 2020-12-15

Similar Documents

Publication Publication Date Title
DK2013175T3 (en) p38 Map kinase inhibitors
CN104151200B (zh) Hdac抑制剂
EP2245012B1 (en) Inhibitors of p38 map kinase
WO2007129036A1 (en) Inhibitors of p38 map kinase
EP2296662A1 (en) Inhibitors of plk
BRPI0609857A2 (pt) compostos inibidores da atividade enzimática de cinase, composição farmacêutica contendo os mesmos e usos
WO2004099127A1 (en) Novel compounds as kinase inhibitors
US20130324501A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
NZ576705A (en) IKK-Beta SERINE-THREONINE PROTEIN KINASE INHIBITORS
JP5732408B2 (ja) 酵素阻害剤
WO2008053158A1 (en) Inhibitors of p38 mitogen-activated protein kinase
MX2010011643A (es) Tiofencarboxamidas sustituidas como inhibidores de la proteina cinasa ikk-beta serina, treonina.
CN101437799B (zh) p38MAP激酶抑制剂
WO2008053136A1 (en) 2-(hetero-)aryl,4-carbonyl substituted pyrazole derivatives as inhibitors of p38 mitogen-activated protein kinase
WO2009136144A1 (en) Purine derivatives suitable for the treatment of cancer, autoimmune and inflammatory diseases

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: CHROMA THERAPEUTICS LTD., GB

Free format text: OLD OWNER(S): CHROMA THERAPEUTICS LTD.

PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 01 MAY 2017 BY CPA GLOBAL

Effective date: 20140320

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAY 2018 BY CPA GLOBAL

Effective date: 20170318

ASS Change of ownership

Owner name: MACROPHAGE PHARMA LIMITED, GB

Effective date: 20170523

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAY 2019 BY CPA GLOBAL

Effective date: 20180315

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAY 2020 BY CPA GLOBAL

Effective date: 20190314

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAY 2021 BY CPA GLOBAL

Effective date: 20200319

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAY 2022 BY CPA GLOBAL

Effective date: 20210318

LAPS Patent lapsed